Assignee
CYTOMX THERAPEUTICS INC
US·72 granted patents·60 pending applications·830 citations·filing 2012–2025
Top patents by PatentIndex Score
132 records- 0198US10875913B2Methods of treatment using activatable anti-EGFR antibodiesCYTOMX THERAPEUTICS INC·Filed 2018·Granted Dec 29, 2020·21 cites·40 claims
- 0298US10533053B2Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptorCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 14, 2020·12 cites·20 claims
- 0398US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0498US10118961B2Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWVCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 6, 2018·34 cites·13 claims
- 0598US10059762B2Anti-EGFR activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·42 cites·41 claims
- 0698US9644016B2Soluble notch receptor proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·34 cites·28 claims
- 0798US9540440B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Jan 10, 2017·31 cites·25 claims
- 0898US9309510B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Apr 12, 2016·26 cites·37 claims
- 0997US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 1097US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 1197US10138272B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 27, 2018·31 cites·43 claims
- 1297US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 1397US9562073B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·32 cites·51 claims
- 1497US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 1597US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 1696US11859010B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·5 cites·13 claims
- 1796US10669337B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 2, 2020·31 cites·16 claims
- 1896US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 1996US8993266B2Proproteins activatable interferon alphaCYTOMX THERAPEUTICS INC·Filed 2012·Granted Mar 31, 2015·28 cites·14 claims
- 2095US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 2195US11180562B2Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodiesCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 23, 2021·5 cites·22 claims
- 2295US11028126B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jun 8, 2021·8 cites·54 claims
- 2395US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 2495US10513549B2Cleavage-activatable interferon-alpha proproteinCYTOMX THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·14 cites·11 claims
- 2595US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 2695US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 2795US9856314B2Activatable antibodies having non-binding steric moieties and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2013·Granted Jan 2, 2018·15 cites·29 claims
- 2895US9737623B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Aug 22, 2017·19 cites·21 claims
- 2995US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 3094US12460017B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·1 cites·12 claims
- 3194US11867695B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 9, 2024·2 cites·26 claims
- 3294US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 3394US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 3494US9517276B2Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2014·Granted Dec 13, 2016·24 cites·31 claims
- 3593US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 3693US10568977B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted Feb 25, 2020·8 cites·20 claims
- 3793US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 3892US12139543B2Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFRCYTOMX THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·1 cites·25 claims
- 3992US11472889B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·7 cites·18 claims
- 4092US10513558B2Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Dec 24, 2019·23 cites·77 claims
- 4191US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 4291US11035859B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 15, 2021·3 cites·37 claims
- 4391US2025215094A1Method of using an anti-epidermal growth factor receptor (egfr) activatable antibody to detect the presence or absence of a cleaving agent and egfrCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4490US12502439B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 4590US11667687B2Masked activatable interferon constructsCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jun 6, 2023·3 cites·30 claims
- 4690US11161906B2Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2014·Granted Nov 2, 2021·12 cites·45 claims
- 4790US10261083B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2014·Granted Apr 16, 2019·14 cites·20 claims
- 4890US2024228603A1Modified antibody compositions, methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4989US2025034755A1Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5087US11220544B2Anti-CD166 antibodies and uses thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jan 11, 2022·8 cites·46 claims
Showing the top 50 of 132 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CYTOMX THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →